Processa Pharmaceuticals, Inc. — Director's Dealing 2025

Jul 28, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Processa Pharmaceuticals, Inc. (PCSA)
CIK: 0001533743
Period of Report: 2025-07-24

Reporting Person: Ng George K (N/A)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2025-07-24	Restricted Stock Units	$0	A	1822471	Acquired		Common Stock (1822471)	Direct

Footnotes

F1: Restricted stock granted under the Processa Pharmaceuticals, Inc. 2019 Omnibus Incentive Plan ("Omnibus Plan"), of which 1,859,318 shares are subject to stockholder approval of the revised Omnibus Plan.

F2: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock, following its vesting on of one-third on January 1, 2026, and one-thirty-sixth each month thereafter until fully vested on January 1, 2028.